MALMÖ, SE / ACCESS Newswire / November 28, 2025 / Ascelia Pharma (STO:ACE)
During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 53,335 series C shares into a total of 53,335 ordinary shares for delivery of shares to participants in the performance-based share saving program that was adopted by the annual general meeting held on 5 May 2022 (LTI 2022).
As of 28 November 2025, the number of shares in Ascelia Pharma AB amounts to 127,902,580 shares, of which 126,868,794 are ordinary shares with one vote each and 1,033,786 are series C shares with 1/10 vote each. The total number of votes in the company amounts to 126,972,172.6.
This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-11-28 15:00 CET.
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
Contacts
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118
Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: jwb@ascelia.com
Tel: +46 735 179 116
This information was submitted for publication, through the agency of the contact persons set out above.
Attachments
Change in Number of Shares and Votes in Ascelia Pharma AB
SOURCE: Ascelia Pharma
View the original press release on ACCESS Newswire
COMTEX_470633617/2457/2025-11-28T09:15:12